1-3 of 3
Ruth M. de Tute, PhD FRCPath
Close
Sort by
Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-136990
Published: 2020
Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 904.
https://doi.org/10.1182/blood.V130.Suppl_1.904.904
Published: 2017
Journal Articles

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Talha Munir, Peter Hillmen, MBChB, PhD, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz-Vicente, Francesca Yates, PhD, Surita Dalal, PhD, Ruth M de Tute, PhD FRCPath, Chris P Fox, Donald Macdonald, Christopher Fegan, MD, Adrian Bloor, Anna Schuh, MD PhD, Gina Doody
Journal: Blood
Blood (2017) 130 (Supplement 1): 3014.
https://doi.org/10.1182/blood.V130.Suppl_1.3014.3014
Published: 2017